Curasan AG (FRA:CUR) to Release Q4 2007 Earnings March 28

Curasan AG (FRA:CUR) will release the fourth quarter earnings for 2007 on Friday, March 28.

Headquartered in Kleinostheim, Germany, Curasan specializes in drug and diagnostic product production and distribution within the regenerative medicine sector.  The company operates in the dental implants, bone and tissue regeneration, tissue engineering and wound healing for dental, spinal and orthopedic applications fields.

Curasan sales activities are focused on the dental implantology market.

REVOIS, the company’s implant system, was introduced to 500 implantologists in 2006.

The company’s primary product is Cerasorb, which is a synthetic bone regeneration product and a base material in tissue and cell engineering.

Other Curasan products include Curavisc, for the treatment of joint arthritis, and stypro, for haemostasis and wound healing.

Curasan Inc, Curasan Benelux b.v and Pro-tec Medizinische Produkte GmbH are the company’s three fully owned subsidiaries.

Curasan AG (FRA:CUR)

For more Earnings related events or to post your own events, visit:

http://events.finditt.com/Events_list.aspx?catid=13